Fresh from the biotech pipeline—2012

Fresh from the biotech pipeline—2012

FDA approvals hit a new high mark in 2012, with a December flurry of approvals. Orphan and fast-track drugs showed strong in the list. Randy Osborne reports.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2013-02, Vol.31 (2), p.100-103
1. Verfasser: Osborne, Randy
Format: Artikel
Sprache:eng
Schlagworte:
631/154/155
631/61/51
Agriculture
Bioinformatics
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Biotechnology industry
Cell- and Tissue-Based Therapy
Drug Approval - economics
Drug Approval - legislation & jurisprudence
FDA approval
Humans
Life Sciences
news-feature
United States
United States Food and Drug Administration - statistics & numerical data
United States Food and Drug Administration - trends
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FDA approvals hit a new high mark in 2012, with a December flurry of approvals. Orphan and fast-track drugs showed strong in the list. Randy Osborne reports.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.2498